Compare CING & LCU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CING | LCU |
|---|---|---|
| Founded | 2012 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Mining |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.2M | 67.9M |
| IPO Year | 2021 | 2025 |
| Metric | CING | LCU |
|---|---|---|
| Price | $4.25 | $4.20 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $21.20 | N/A |
| AVG Volume (30 Days) | ★ 114.5K | 11.3K |
| Earning Date | 11-16-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 56.47 | ★ 400.00 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.16 | $4.00 |
| 52 Week High | $11.89 | $5.21 |
| Indicator | CING | LCU |
|---|---|---|
| Relative Strength Index (RSI) | 36.16 | 53.46 |
| Support Level | $4.19 | $4.07 |
| Resistance Level | $5.31 | $4.97 |
| Average True Range (ATR) | 0.31 | 0.46 |
| MACD | -0.07 | 0.00 |
| Stochastic Oscillator | 3.50 | 31.15 |
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.